糖尿病性神経障害の市場規模、シェア、成長分析、疾患タイプ別、薬剤クラス別、流通チャネル別、地域別 - 産業別予測、2024～2031年

糖尿病性神経障害の世界市場規模は、2022年に36億米ドルと評価され、2023年の38億5,000万米ドルから2031年には65億6,000万米ドルに成長し、予測期間（2024-2031年）のCAGRは6.9％で成長する見通しです。

糖尿病性神経障害は、高血糖に関連して神経を損傷する疾患であり、長期にわたる糖尿病患者にとって大きな課題となっています。現在のところ治療法はないため、効果的な管理と予防戦略が極めて重要です。この複雑さは、規制当局が新しい治療薬や治療アプローチを承認する必要性を強調しています。糖尿病患者の糖尿病性神経障害有病率が高いことから、この分野で事業を展開する企業には大きな市場機会が存在します。認知度と診断が向上するにつれ、糖尿病患者のニーズに対応した革新的なソリューションに対する需要が急増することが予想され、ヘルスケア市場の成長と開拓に有利な展望がもたらされます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2023年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 技術の進歩
• 規制情勢
• ケーススタディ

糖尿病性神経障害市場規模：疾患タイプ別

• 市場概要
• 末梢神経障害
• 自律神経障害
• 近位神経障害
• 局所神経障害

糖尿病性神経障害市場規模：薬剤クラス別

• 市場概要
• カプサイシン
• オピオイド
  • モルヒネ
  • その他
• 非ステロイド性抗炎症薬（NSAID）
  • イブプロフェン
  • ナプロキセン
• 抗うつ薬
  • 三環系抗うつ薬（Tcas）
  • アミトリプチリン
  • イミプラミン
  • セロトニンおよびノルエピネフリン再取り込み阻害剤（SNRIS）
  • デュロキセチン
  • 選択的セロトニン再取り込み阻害薬（SSRI）
  • シタロプラム
  • パロキセチン
  • 抗けいれん薬
  • ガバペンチン
  • プレガバリン
  • トピラマート
• その他

糖尿病性神経障害市場規模：流通チャネル別

• 市場概要
• 病院薬局
• 小売薬局

糖尿病性神経障害市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2023年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2021-2023）

主要企業プロファイル

• Abbott Laboratories
• Eli Lilly and Company
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Lupin Pharmaceuticals, Inc.
• Astellas Pharma US, Inc.
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• NeuroMetrix Inc.
• Helixmith Co., Ltd.
• Johnson & Johnson Services, Inc.
• Daiichi Sankyo Company, Limited
• Ionis Pharmaceuticals, Inc.
• Akcea Therapeutics, Inc.
• Alfasigma USA, Inc.
• ExeGi Pharma LLC

結論と推奨事項

Global Diabetic Neuropathy Market size was valued at USD 3.6 billion in 2022 and is poised to grow from USD 3.85 billion in 2023 to USD 6.56 billion by 2031, growing at a CAGR of 6.9% during the forecast period (2024-2031).

Diabetic neuropathy, a nerve-damaging condition linked to hyperglycemia, poses significant challenges for long-term diabetes sufferers, where symptoms often go unnoticed until considerable nerve damage occurs. As there is currently no cure, effective management and preventive strategies are crucial. This complexity emphasizes the need for regulatory agencies to approve new treatment products and therapeutic approaches. With the high prevalence of diabetic neuropathy among individuals with diabetes, there exists a substantial market opportunity for companies operating in this sector. As awareness and diagnosis improve, businesses can expect a surge in demand for innovative solutions tailored to address the needs of those affected by this condition, presenting lucrative prospects for growth and development in the healthcare market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetic Neuropathy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetic Neuropathy Market Segmental Analysis

Global Diabetic Neuropathy Market is segmented by disorder type, drug class, distribution channel and region. Based on disorder type, the market is segmented into peripheral neuropathy, autonomic neuropathy, proximal neuropathy and focal neuropathy. Based on drug class, the market is segmented into capsaicin, opioid, non-steroidal anti-inflammatory drugs (NSAIDS), antidepressants and other. Based on distribution channel, the market is segmented into hospitals pharmacies and retail pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Diabetic Neuropathy Market

The Global Diabetic Neuropathy market is primarily driven by the increasing prevalence of diabetes worldwide, leading to a higher demand for diabetic neuropathy treatment. As diabetes rates continue to rise, the market is expected to experience steady growth throughout the forecast period. Contributing factors include the rise in obesity, coronary heart disease, and various complications associated with diabetes, such as neuropathy. Additionally, urbanization plays a significant role in this trend, fostering sedentary lifestyles characterized by increased carbohydrate intake and reduced physical activity, which further exacerbates the incidence of diabetes and, consequently, the need for effective management of diabetic neuropathy.

Restraints in the Global Diabetic Neuropathy Market

The Global Diabetic Neuropathy market faces several restraints that impede its growth potential. One significant challenge is the high cost of medications specifically designed for treating this condition, which may deter patients from pursuing pharmaceutical options. Additionally, the increasing popularity of alternative treatments, such as radiotherapy and physiotherapy, presents competition as these methods are often perceived as more comfortable and capable of delivering satisfactory results. Furthermore, stringent regulations, instances of product recalls, and delays in obtaining clearances from regulatory bodies like the Food and Drug Administration also contribute to the difficulties faced by the market in expanding its reach and efficacy.

Market Trends of the Global Diabetic Neuropathy Market

The Global Diabetic Neuropathy market is witnessing a dynamic trend characterized by innovations in high-tech therapeutic solutions aimed at enhancing treatment efficacy. During the forecast period, companies are focusing on developing advanced products, including transdermal patches, mouthwashes, and powders, to address the complexities of diabetic neuropathy. The introduction of sophisticated medication delivery systems, such as needle-free injection devices, is emerging as a key strategy to mitigate challenges associated with traditional pharmaceutical methods. This surge in demand for novel drug delivery forms-spanning oral, transdermal, parenteral, and inhalation routes-is propelling market growth, reflecting an increasing consumer and healthcare provider interest in effective management of the condition.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies

Global Diabetic Neuropathy Market Size by Disorder Type & CAGR (2024-2031)

• Market Overview
• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy

Global Diabetic Neuropathy Market Size by Drug Class & CAGR (2024-2031)

• Market Overview
• Capsaicin
• Opioid
  • Morphine
  • Others
• Non-Steroidal Anti-Inflammatory Drugs (Nsaids)
  • Ibuprofen
  • Naproxen
• Antidepressants
  • Tricyclic Antidepressants (Tcas)
  • Amitriptyline
  • Imipramine
  • Serotonin and Norepinephrine Reuptake Inhibitors (Snris)
  • Duloxetine
  • Selective Serotonin Reuptake Inhibitors (Ssris)
  • Citalopram
  • Paroxetine
  • Anticonvulsant Drugs
  • Gabapentin
  • Pregabalin
  • Topiramate
• Other

Global Diabetic Neuropathy Market Size by Distribution Channel & CAGR (2024-2031)

• Market Overview
• Hospitals Pharmacies
• Retail Pharmacies

Global Diabetic Neuropathy Market Size & CAGR (2024-2031)

• North America (Disorder Type, Drug Class, Distribution Channel)
  • USA
  • Canada
• Europe (Disorder Type, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disorder Type, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disorder Type, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disorder Type, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma US, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeuroMetrix Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helixmith Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akcea Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alfasigma USA, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ExeGi Pharma LLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations